Mixed results FOR CLL treatments availble through the CDF as the final verdict following the latest round of the CDF prioritisation review is made available. cllsupport.org.uk/news/posi...
NHS England have published today the new version 6 of the Cancer Drugs Fund list. Effective from today.
This new version supersedes earlier versions and follows on from all formal appeals and discussions between NCDF and drug companies following the September delisting announcements . This is now available. on the NHS England website: england.nhs.uk/ourwork/pe/cdf/ PDF of Version 6 Cancer Drugs Fund list england.nhs.uk/wp-content/u...
The good News: Ibrutinib has been retained on the CDF list with a small adjustment to inclusion criteria. This reverses the earlier September decision to remove it with one small exception.
This means that new CDF applications to access ibrutinib for treatment of relapsed/refractory CLL will now continue virtually as it was before the July re- prioritization review, NICE are also appraising Ibrutinb for long term availability through NHS England & Wales.
The Bad news: Bendamustine has been removed from the CDF list for treating relapsed CLL.
Read about the Blood Cancers Alliance response to Cancer Drugs Fund delistings - Letter published in the Times today healthunlocked.com/cllsuppo...
Tricia will be updating soon on our campaign and letters to MPs and the need for us to keep up pressure and continue with pressing for access .
Nick